Table 3.
Metabolites significantly associated to participant age, sample batch and/or altered in SPMS patients compared with controls with corresponding p-values as well as their within-day reproducibility and long-term stability estimated with CV
| Metabolite | Class | Analysis method | Quantification | Age (p-value) | Batch (p-value) | SPMS vs control (p-value) | CV (%) (within) | CV (%) (between) | n (CV) |
|---|---|---|---|---|---|---|---|---|---|
| AC (0:0) | Acylcarnitines | FIA | Quantitative | n.s | n.s | n.s | 3 | 9 | 12 |
| AC (14:1) | Acylcarnitines | FIA | Relative Quantitative | n.s | < 0.001 | n.s | 11 | 46 | 3 |
| AC (2:0) | Acylcarnitines | FIA | Quantitative | n.s | 0.015 | n.s | 13 | 24 | 12 |
| AC (4:0-DC) | Acylcarnitines | FIA | Relative Quantitative | n.s | < 0.001 | n.s | 28 | 18 | 8 |
| Alanine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 4 | 3 | 12 |
| Arginine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 1 | 1 | 12 |
| Asparagine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 2 | 2 | 12 |
| Citrulline | Amino acids | LC | Quantitative | n.s | 0.017 | n.s | 4 | 3 | 10 |
| Glutamine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 2 | 2 | 12 |
| Glycine | Amino acids | LC | Quantitative | n.s | 0.020 | 0.016 | 2 | 2 | 12 |
| Histidine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 1 | 1 | 12 |
| Isoleucine | Amino acids | LC | Quantitative | – | – | – | 8 | 13 | 4 |
| Lysine | Amino acids | LC | Quantitative | 0.017 | n.s | n.s | 2 | 2 | 12 |
| Methionine | Amino acids | LC | Quantitative | n.s | 0.009 | n.s | 2 | 1 | 12 |
| Ornithine | Amino acids | LC | Quantitative with Restrictions | n.s | n.s | n.s | 3 | 3 | 12 |
| Phenylalanine | Amino acids | LC | Quantitative | 0.040 | n.s | n.s | 3 | 3 | 12 |
| Serine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 2 | 1 | 12 |
| Threonine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 1 | 1 | 12 |
| Tryptophan | Amino acids | LC | Quantitative | n.s | n.s | n.s | 7 | 11 | 12 |
| Tyrosine | Amino acids | LC | Quantitative | n.s | n.s | n.s | 1 | 1 | 11 |
| Valine | Amino acids | LC | Quantitative | 0.008 | n.s | n.s | 5 | 3 | 12 |
| xLeucine | Amino acids | LC | Quantitative | 0.001 | n.s | n.s | 3 | 3 | 12 |
| ADMA | Biogenic amines | LC | Quantitative | n.s | < 0.001 | 0.009 | 9 | 5 | 12 |
| Creatinine | Biogenic amines | LC | Quantitative | n.s | n.s | n.s | 7 | 8 | 12 |
| Kynurenine | Biogenic amines | LC | Quantitative | n.s | 0.007 | n.s | – | – | – |
| Putrescine | Biogenic amines | LC | Quantitative | n.s | n.s | n.s | 7 | 7 | 9 |
| SDMA | Biogenic amines | LC | Quantitative | n.s | n.s | n.s | 3 | 4 | 12 |
| t4-OH-Pro | Biogenic amines | LC | Quantitative | n.s | n.s | n.s | 3 | 2 | 12 |
| Taurine | Biogenic amines | LC | Quantitative | n.s | n.s | n.s | 2 | 2 | 12 |
| CE (18:1) | Cholesterol esters | FIA | Relative Quantitative | n.s | 0.009 | n.s | 73 | 70 | 6 |
| CE (18:2) | Cholesterol esters | FIA | Relative Quantitative | n.s | 0.033 | n.s | 79 | 89 | 9 |
| CE (20:4) | Cholesterol esters | FIA | Relative Quantitative | – | – | – | 8 | 12 | 7 |
| TG (50:2) | Glycerides | FIA | Relative Quantitative | – | – | – | 35 | 30 | 4 |
| TG (52:4) | Glycerides | FIA | Relative Quantitative | n.s | n.s | n.s | 71 | 112 | 11 |
| TG (53:4) | Glycerides | FIA | Relative Quantitative | n.s | n.s | n.s | 13 | 50 | 5 |
| PC (29:1) | Glycerophospholipids | FIA | Relative Quantitative | – | – | – | 68 | 40 | 4 |
| PC (32:0) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 14 | 11 | 12 |
| PC (34:1) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 6 | 5 | 12 |
| PC (34:2) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 13 | 10 | 12 |
| PC (36:1) | Glycerophospholipids | FIA | Relative Quantitative | – | – | – | 14 | 15 | 12 |
| PC (36:2) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 13 | 3 | 3 |
| PC (38:5) | Glycerophospholipids | FIA | Relative Quantitative | – | – | – | 13 | 21 | 5 |
| PC (40:3) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 42 | 82 | 6 |
| PC (40:6) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 27 | 10 | 5 |
| PC (44:5) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 46 | 19 | 9 |
| PC-O (31:1) | Glycerophospholipids | FIA | Relative Quantitative | n.s | < 0.001 | n.s | – | – | – |
| PC-O (33:0) | Glycerophospholipids | FIA | Relative Quantitative | n.s | n.s | n.s | 27 | 47 | 8 |
| PC-O (34:0) | Glycerophospholipids | FIA | Relative Quantitative | n.s | 0.024 | 0.046 | 28 | 21 | 9 |
| PC-O (34:2) | Glycerophospholipids | FIA | Relative Quantitative | – | – | NA | 85 | 43 | 9 |
| PC-O (36:2) | Glycerophospholipids | FIA | Relative Quantitative | n.s | 0.012 | n.s | – | – | – |
| SM (34:1) | Sphingolipids | FIA | Relative Quantitative | n.s | 0.008 | n.s | 34 | 33 | 12 |
| Hexoses | Sugars | FIA | Quantitative | n.s | n.s | 0.010 | 2 | 2 | 12 |
n.s. non-significant